Table 1 Baseline demographic data and clinical characteristics of the study population
Variable | HPR (n = 233) | Non-HPR (n = 441) | p |
|---|---|---|---|
Age, y | 61.7 ± 9.3 | 62.0 ± 9.1 | 0.65 |
Males, n (%) | 141 (60.5) | 287 (65.1) | 0.27 |
Smoking, n (%) | 104 (44.6) | 204 (46.3) | 0.69 |
Hypertension, n (%) | 169 (72.5) | 292 (66.2) | 0.09 |
BMI (kg/m2) | 26.1 ± 3.4 | 25.9 ± 4.0 | 0.62 |
Triglycerides (mmol/L) | 2.4 ± 1.8 | 2.3 ± 1.8 | 0.23 |
Total cholesterol (mmol/L) | 4.2 ± 1.3 | 4.1 ± 1.1 | 0.12 |
LDL-C (mmol/L) | 2.3 ± 0.9 | 2.2 ± 0.8 | 0.53 |
HDL-C (mmol/L) | 1.1 ± 0.4 | 1.2 ± 0.4 | 0.85 |
HbA1C (%) | 7.3 ± 1.1 | 7.4 ± 1.3 | 0.59 |
Hyperlipidemia, n (%) | 127 (54.5) | 223 (50.6) | 0.33 |
Insulin-treated diabetes, n (%) | 61 (26.2) | 97 (22.0) | 0.22 |
Previous MI, n (%) | 48 (20.6) | 102 (23.1) | 0.45 |
Previous stroke, n (%) | 27 (11.6) | 36 (8.2) | 0.15 |
Chronic renal dysfunction, n (%) | 23 (9.9) | 52 (11.8) | 0.52 |
Essential medicine, n (%) | |||
 ACEI/ARB | 152 (62.5) | 255 (57.8) | 0.06 |
 β-blocker | 139 (59.7) | 275 (62.4) | 0.50 |
 Calcium channel blocker | 57 (24.5) | 123 (27.9) | 0.34 |
 Statins | 211 (90.6) | 394 (89.3) | 0.62 |
 Nitrates | 110 (47.2) | 193 (43.8) | 0.39 |